Citation

Santens P, Ventura M. Acta Neurol. Belg. 2003; 103(3): 159-163.

Copyright

(Copyright © 2003, Acta Medica Belgica)

DOI

unavailable

PMID

unavailable

Abstract

In this report the results of a Belgian multicenter 24-week open-label study with donepezil in the treatment of mild to moderate Alzheimer's disease are described. Efficacy and safety were evaluated in a sample of 200 patients recruited in 25 Belgian centers. No significant changes could be found in cognition and behaviour over this 6-month period. Changes in daily functioning were small. Safety data were comparable to those reported in international trials. These results suggest that the findings of more robust double-blind, placebo-controlled studies can be confirmed in real life situations.

Language: en